Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey.
J Nephrol. 2012 Sep-Oct;25(5):825-32. doi: 10.5301/jn.5000072.
Although intravenous iron (IVI) is thought to have potential inflammatory and atherogenic effects, there are not enough studies comparing these effects in chronic hemodialysis (HD) patients. In this study, different doses and types of IVI were examined for effects on inflammation and oxidative stress.
Chronic HD patients (n=101) were grouped into those not receiving IVI (group 1, n=29), those getting intermittent iron sucrose (group 2, n=25), those receiving intermittent iron dextran (group 3, n=24) and those getting a once monthly total dose of iron dextran (group 4, n=23). Malondialdehyde (MDA), advanced oxidation protein product (AOPP), C-reactive protein (CRP) and TNF-α levels were measured on days 0, 2, 7 and 28.
Groups were similar regarding age, sex, hemoglobin, iron indices and total amount of IVI given monthly. Although MDA levels at days 7 and 28, AOPP levels at days 0 and 28, CRP levels at day 28 and TNF-α level at day 7 were higher than at other days, there were no significant differences between the IVI groups on statistical analysis.
The different types and doses (intermittent or once monthly total dose) of IVI treatments are well tolerated without negative effects on the markers of lipid and protein oxidation and inflammatory indices in chronic HD patients.
虽然静脉铁（IVI）被认为具有潜在的炎症和动脉粥样硬化作用，但目前还没有足够的研究比较慢性血液透析（HD）患者的这些作用。在这项研究中，检查了不同剂量和类型的 IVI 对炎症和氧化应激的影响。
将慢性 HD 患者（n=101）分为未接受 IVI 的患者（第 1 组，n=29）、接受间歇性蔗糖铁（第 2 组，n=25）、接受间歇性铁右旋糖酐（第 3 组，n=24）和接受每月一次铁右旋糖酐总剂量的患者（第 4 组，n=23）。在第 0、2、7 和 28 天测量丙二醛（MDA）、晚期氧化蛋白产物（AOPP）、C-反应蛋白（CRP）和 TNF-α水平。
各组在年龄、性别、血红蛋白、铁指标和每月给予的 IVI 总量方面相似。尽管第 7 和 28 天的 MDA 水平、第 0 和 28 天的 AOPP 水平、第 28 天的 CRP 水平和第 7 天的 TNF-α水平高于其他天数，但在统计分析中 IVI 组之间没有显著差异。
不同类型和剂量（间歇性或每月总剂量）的 IVI 治疗在慢性 HD 患者中耐受性良好，对脂质和蛋白质氧化以及炎症指标没有负面影响。
